ELIZABETH SHPALL to Cytomegalovirus Infections
This is a "connection" page, showing publications ELIZABETH SHPALL has written about Cytomegalovirus Infections.
Connection Strength
1.930
-
Another tool against cytomegalovirus after allogeneic hematopoietic cell transplantation. J Clin Invest. 2023 05 15; 133(10).
Score: 0.647
-
Mycophenolate mofetil is associated with inferior overall survival in cytomegalovirus-seropositive patients with acute myeloid leukemia undergoing hematopoietic cell transplantation. Haematologica. 2024 07 01; 109(7):2321-2325.
Score: 0.175
-
Generation of Non-Alloreactive Antiviral Central Memory CD8 Human Veto T Cells for Cell Therapy. Transplant Cell Ther. 2024 Jan; 30(1):71.e1-71.e13.
Score: 0.167
-
Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial. Clin Cancer Res. 2020 07 15; 26(14):3565-3577.
Score: 0.131
-
The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients. J Infect Dis. 2019 02 23; 219(6):898-907.
Score: 0.121
-
HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant. Curr Res Transl Med. 2019 05; 67(2):51-55.
Score: 0.120
-
Donor NKG2C Copy Number: An Independent Predictor for CMV Reactivation After Double Cord Blood Transplantation. Front Immunol. 2018; 9:2444.
Score: 0.118
-
Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: A single-center experience. Antiviral Res. 2016 10; 134:58-62.
Score: 0.102
-
Utility of the Enzyme-Linked Immunospot Interferon-?-Release Assay to Predict the Risk of Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients. J Infect Dis. 2016 Jun 01; 213(11):1701-7.
Score: 0.098
-
Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013 Jun 27; 121(26):5113-23.
Score: 0.081
-
Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant. 2007 Jul; 40(2):125-36.
Score: 0.054
-
Post-mortem incidental finding of cytomegalovirus oophoritis after an allogeneic stem cell transplant. Bone Marrow Transplant. 1999 Jun; 23(12):1323-4.
Score: 0.031
-
Foundation for the Accreditation of Hematopoietic Cell Therapy (FAHCT) response to FDA (Docket no. 97N-0068). FAHCT Board of Directors. J Hematother. 1997 Aug; 6(4):287-9.
Score: 0.027
-
Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System. J Vis Exp. 2015 Oct 05; (104).
Score: 0.024
-
Expanding cytotoxic T lymphocytes from umbilical cord blood that target cytomegalovirus, Epstein-Barr virus, and adenovirus. J Vis Exp. 2012 May 07; (63):e3627.
Score: 0.019
-
Factors affecting mortality following myeloablative cord blood transplantation in adults: a pooled analysis of three international registries. Bone Marrow Transplant. 2011 Jan; 46(1):70-6.
Score: 0.016